Salarius Pharmaceuticals (SLRX) Competitors $5.28 +0.01 (+0.19%) As of 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. ALBT, ERNA, INAB, APRE, DWTX, ADXN, APM, KPRX, PCSA, and RNAZShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Avalon GloboCare (ALBT), Ernexa Therapeutics (ERNA), IN8bio (INAB), Aprea Therapeutics (APRE), Dogwood Therapeutics (DWTX), Addex Therapeutics (ADXN), Aptorum Group (APM), Kiora Pharmaceuticals (KPRX), Heatwurx (PCSA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors Avalon GloboCare Ernexa Therapeutics IN8bio Aprea Therapeutics Dogwood Therapeutics Addex Therapeutics Aptorum Group Kiora Pharmaceuticals Heatwurx TransCode Therapeutics Avalon GloboCare (NASDAQ:ALBT) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership. Which has preferable valuation & earnings, ALBT or SLRX? Salarius Pharmaceuticals has lower revenue, but higher earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalon GloboCare$1.33M8.16-$7.90M-$19.96-0.14Salarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.12 Is ALBT or SLRX more profitable? Salarius Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avalon GloboCare-1,451.94% N/A -75.12% Salarius Pharmaceuticals N/A -556.47%-192.35% Do insiders and institutionals hold more shares of ALBT or SLRX? 1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. 37.3% of Avalon GloboCare shares are owned by insiders. Comparatively, 1.2% of Salarius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor ALBT or SLRX? In the previous week, Salarius Pharmaceuticals had 4 more articles in the media than Avalon GloboCare. MarketBeat recorded 6 mentions for Salarius Pharmaceuticals and 2 mentions for Avalon GloboCare. Salarius Pharmaceuticals' average media sentiment score of 0.48 beat Avalon GloboCare's score of 0.45 indicating that Salarius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Avalon GloboCare Neutral Salarius Pharmaceuticals Neutral Which has more risk and volatility, ALBT or SLRX? Avalon GloboCare has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. SummarySalarius Pharmaceuticals beats Avalon GloboCare on 7 of the 12 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.69M$2.84B$5.82B$10.17BDividend YieldN/A56.65%5.69%4.60%P/E Ratio-0.1223.5974.6725.98Price / SalesN/A544.01454.5485.61Price / CashN/A169.2537.0859.91Price / Book0.375.3712.186.31Net Income-$5.58M$32.95M$3.29B$270.86M7 Day Performance12.10%1.43%1.08%3.46%1 Month Performance-36.00%8.48%7.32%6.57%1 Year Performance-77.14%0.53%63.11%28.39% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.3145 of 5 stars$5.28+0.2%N/A-78.0%$2.69MN/A-0.1220Short Interest ↑ALBTAvalon GloboCare0.942 of 5 stars$2.51+6.4%N/A-39.6%$9.64M$1.33M-0.135Short Interest ↑Gap UpERNAErnexa Therapeutics1.0063 of 5 stars$1.26+1.2%N/A-94.1%$9.63M$580K-0.1510Positive NewsGap UpINABIN8bio3.6814 of 5 stars$2.06-4.6%$180.00+8,637.9%-77.0%$9.35MN/A-0.2320Positive NewsShort Interest ↓APREAprea Therapeutics2.7788 of 5 stars$1.60-0.4%$15.50+866.3%-51.2%$9.35M$1.50M-0.697Short Interest ↑Gap DownDWTXDogwood Therapeutics2.1064 of 5 stars$4.87-0.6%$10.00+105.3%N/A$9.31MN/A-0.265Gap DownADXNAddex Therapeutics2.8454 of 5 stars$8.70+7.5%$30.00+245.0%-14.8%$9.22M$460K-25.5830Positive NewsGap UpAPMAptorum Group0.8294 of 5 stars$1.72+0.6%N/A-34.2%$9.20M$430K0.0030Short Interest ↑Gap UpKPRXKiora Pharmaceuticals2.3855 of 5 stars$2.65-1.7%$10.00+278.1%-24.6%$9.07M$16.02M-0.9110Short Interest ↑PCSAHeatwurx3.5321 of 5 stars$0.18-3.0%$1.00+465.0%-85.7%$8.91MN/A-0.0820Short Interest ↓RNAZTransCode Therapeutics2.3711 of 5 stars$10.73-1.2%$280.00+2,509.5%-99.9%$8.91MN/A0.009Gap Up Related Companies and Tools Related Companies ALBT Competitors ERNA Competitors INAB Competitors APRE Competitors DWTX Competitors ADXN Competitors APM Competitors KPRX Competitors PCSA Competitors RNAZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRX Stock Alerts